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cense.Abstract Introduction: SLE is a systemic autoimmune disease with polyclonal B cell hyperactiv-
ity, spontaneous lymphocyte proliferation, and the production of pathogenic antibodies to self-anti-
gens. Interleukin-6 is a pleiotropic cytokine with diverse functions including B-cell growth and
differentiation. IL-6 levels have been shown to be affected by single nucleotide change from G to
C at position 174 in the promoter region of the IL-6 gene.
Aim of the work: To ﬁnd out whether single nucleotide polymorphisms in the promoter region of
the IL-6 gene (174 G/C) constitute a genetic susceptibility for SLE and its association with various
disease clinical and immunological features.
Patients and methods: Forty-two female SLE patients and 40 healthy controls were genotyped
for IL-6 gene promoter region (174 G/C) polymorphism using PCR. SLE patients satisﬁed the
1982 revised criteria of the American Rheumatism Association for the classiﬁcation of SLE, with
a mean age of 32.4 ± 5.5 years and mean disease duration of 5.7 ± 1.5 years. The healthy controls
were matched for age and sex, with a mean age of 31.7 ± 4.9 years. All subjects were recruited from
the Rheumatology and Rehabilitation and Internal Medicine Departments, Kasr El Aini Hospitals.549170626.
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70 D. Abbas et al.SLE clinical and laboratory features were recorded including constitutional, hematological, joint,
renal, and neuropsychiatric manifestations, oral ulcers, serositis, malar rash, and photosensitivity
and CBC, liver, kidney functions and serum C3 and C4 levels. Positivity for ANAs, Anti-dsDNA
and Anti-Sm antibodies were determined.
Results: Genotypic and allelic distributions showed no signiﬁcant differences between SLE
patients and controls. The frequency of G allele was higher than C allele in both patients (83.3%
vs. 16.7%) and controls (85% vs. 15%). SLE patients with GG genotype showed signiﬁcantly
higher frequencies and increased risk of; constitutional manifestations at disease onset
(P= 0.02), OR (95% CI) = 6.55 (1.22–35.12), photosensitivity (P= 0.03), OR (95% CI) = 4.67
(1.11–19.54), hematological disorders (P= 0.02), OR (95% CI) = 5.5 (1.29–23.39) and positivity
of ANAs and Anti-dsDNA [P= 0.046, 0.03: OR (95% CI) = 7 (1.1–45.44), 6.43 (1.23–33.65),
respectively]. Furthermore, those patients had signiﬁcantly lower mean WBCs counts when com-
pared to SLE patients with (GC and CC) genotypes (4.54 ± 1.31 vs. 5.98 ± 1.04/dl, P= 0.002).
Twenty-ﬁve patients had lupus nephritis (LN) proved by renal biopsy but none of them had CC
genotype. LN patients with GG genotype had nearly similar mean 24-h proteinuria to those with
GC genotype (2.93 ± 1.07 vs. 2.68 ± 1.06 g/24 h and P= 0.39). No signiﬁcant difference was
found in IL-6 genotype and allele distributions when patients with diffuse proliferative glomerulo-
nephritis (class IV), which has the worst prognostic outcome, were compared to patients with non-
class IV glomerulonephritis (classes II and III) [P= 0.12, 0.15, respectively].
Conclusion: IL-6 promoter region (174 G/C) polymorphism does not confer susceptibility to
SLE but it is related to the presence of distinct clinical and immunological features. Furthermore,
the increased frequency of the high-response G allele suggests that a genetically determined high IL-
6 response may have a pathogenic role.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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SLE is a systemic autoimmune disease with extremely diverse
clinical presentations and a multitude of clinical symptoms
which involves multiple organ systems [1].
The main features of autoimmunity in SLE are polyclonal
B cell hyperactivity, spontaneous lymphocyte proliferation,
and the production of pathogenic antibodies to self-antigens.
B cell abnormalities in SLE also include excess cytokine pro-
duction, autoantigen presentation to T cells and modulation
of the function of other immune cells [2]. Thus, SLE is gener-
ally considered a B cell disease, a theme strengthened by the
efﬁcacy of therapies targeting B cells [3].
Although the initiating immunological event in SLE re-
mains unknown, it has been shown that an imbalance between
depressed TH1 cell cytokines which promote cell mediated
immunity and enhanced TH2 cell cytokines which support hu-
moral immunity, play a crucial role in the pathophysiological
cascade. There is accumulating evidence from experimental
and clinical studies to suggest that interleukin-6 (IL-6) is a cen-
tral cytokine in this context [4].
Interleukin-6 is a pleiotropic cytokine with diverse func-
tions including stimulation of the hepatic acute phase response
to infection and injury [5], differentiation and/or activation of
macrophages and T cells, B-cell growth and differentiation fac-
tor that induces the ﬁnal maturation of IL-4-preactivated B-
cell into immunoglobulin-secreting plasma cells, support of
multipotential colony formation by hematopoietic stem cells,
and neural differentiation [4,6].
Interleukin-6 is not constitutively expressed but is highly
inducible and is produced in response to a number of inﬂam-
matory stimuli such as IL1, platelet-derived growth factor,
TNFa, bacterial products such as endotoxin and viral infec-tion. Many cell types produce IL6 in response to noxious stim-
uli, including monocytes/macrophages, ﬁbroblasts, endothelial
cells, adipocytes, T cells, and mast cells [6].
Higher levels of IL-6 mRNA in SLE PBMC and IL-6 pro-
tein in serum and involved kidneys of patients with active dis-
ease have been shown and that endogenous IL-6 is essential for
SLE B cell hyperactivity [7–9]. A number of studies have re-
ported a correlation between SLE disease activity and IL-6
[10]. In murine SLE, treatment with anti-IL-6 antibody abro-
gated disease, supported the concept that IL-6 has an impor-
tant pathogenic role in lupus [11].
IL-6 over-expression in SLE could result from an abun-
dance of up-regulating factors and/or polymorphisms in re-
gions having gene regulatory implications, however, several
reports are in support of the latter [12].
The IL-6 gene has been mapped to the short arm of
chromosome 7 at location 21–15 [13]. The entire IL-6 gene is
organized into ﬁve exons and four introns. The translation
of IL-6 RNA and post-translational processing results in the
formation of a 21- to 28-kDa protein with 128 amino acids
[14].
IL-6 is regulated mainly at the transcriptional level by reg-
ulatory elements in the 50 ﬂanking region of the gene encoding
IL-6. Several polymorphisms in the promoter region of IL-6
gene have been described [15–17]. At this region, 572 G/C
and 174 G/C polymorphisms are key regulators of IL-6 gene
and downstream protein levels [18].
The single nucleotide change from G to C at position 174
has been shown to affect IL-6 levels [19]. This polymorphism
lies immediately upstream of a multi-responsive element lo-
cated at positions 173 to 151 relative to the transcription
start site. This element has been shown to be important in
IL-1 and TNF modulated expression of IL-6 [15,16].
Figure 1 Alleles of the IL-6 promoter polymorphism (174 G/
C) as shown by agarose gel electrophoresis. Ladder: 100-bp DNA
marker. Lane 1, 2, 4, 6, 7, 9: homozygous GG (121 bp), lane 3, 5:
heterozygous G/C (121 and 136 bp), lane 8, 10: homozygous CC
(136 bp).
Promoter region polymorphism (174 G/C) of interleukin-6 gene and SLE; are they associated? 71In view of these ﬁndings, we conducted the study to ﬁnd out
whether single nucleotide polymorphisms located in the pro-
moter region of the IL-6 gene (174 G/C) constitute a genetic
susceptibility for SLE and its association with various disease
clinical and immunological features.
2. Patients and methods
2.1. SLE patients and healthy controls
Blood samples (3 ml each) were collected from 42 female SLE
patients and 40 healthy volunteers, from the Rheumatology and
Rehabilitation and Internal Medicine Departments, Kasr El
Aini Hospitals, Cairo University, after taking their consent.
The patients satisﬁed the 1982 revised criteria of the American
Rheumatism Association for the classiﬁcation of SLE [20],
with a mean age of 32.4 ± 5.5 years and mean disease dura-
tion of 5.7 ± 1.5 years. The controls were matched for age
and sex with a mean age of 31.7 ± 4.9 years.
SLE patients’ medical histories were reviewed from the dis-
ease onset until admission to the study. Clinical and laboratory
features were recorded including constitutional, hematological,
joint, renal, and neuropsychiatric manifestations, oral ulcers,
serositis, malar rash, and photosensitivity and CBC, liver, kid-
ney functions and serum C3 and C4 levels. To investigate auto-
antibody status; ANAs, Anti-dsDNA and Anti-Sm antibodies
were tested.
- CNS disease included: cerebrovascular disease, demyelinat-
ing syndrome, aseptic meningitis, myelopathy, seizures,
cognitive dysfunction, psychosis and mood disorders [21].
Lupus nephritis was deﬁned by the presence of persistent
24-h proteinuria >0.5 g and/or active sediment (cellular
casts-red cell, granular, tubular, or mixed) and/or serum
creatinine >1.2 mg/dl and/or renal biopsy evidence of
lupus nephritis (immune complex deposition). WHO crite-
ria were used to classify the histopathological ﬁndings [22].
The healthy controls were unrelated to patients and be-
longed to the same ethnic background and shared similar so-
cial conditions to the patients. Exclusion criteria; signiﬁcant
cardiovascular, pulmonary, metabolic, rheumatic, renal dis-
eases and other diseases with a known genetic or hereditary
predisposition.
2.2. IL-6. (174 G/C) genotyping
Genomic DNA was extracted from the whole blood using EZ-
10 spin column Blood Genomic DNA Minipreps kit (Biosys-
tems, California, US) and stored at 20 C until genotyping
was performed.
Genotyping of the single nucleotide polymorphisms in the
promoter region of the IL-6 gene (174 G/C) was carried
out by polymerase chain reaction. Primer sequences (forward
primer G: 50-GCACTTTT CCCCCTAGTTGTGTCTTACG-
30; forward primer C: 50-ATGACGACCTAAGCTTTACTTT
TCCCCCTAGTTGTGT CTTGAC-30; and reverse primer: 50-
ATAAATCTTTGTTGGAGGGTGAGG-30) were used. Each
PCR contained 10 ng genomic DNA in a ﬁnal volume of 20 ll
reaction which included 10 pmol of each primer (Operon Bio-
technologies, Germany), 1 U Taq DNA polymerase (PromegaCorporation, US,), 0.1 mM dNTP mix (Promega Corporation,
US,), 2.0 ll Taq buffer with KCl, and 1.0 mMMgCl2. PCRwas
performed on an automated DNA thermal cycle (Peq lab, Bio-
technologie) with procedure as follows: initial denaturation at
95 for 10 min, 40 cycles of ampliﬁcation consisting of denatur-
ation at 94 C for 30 s, annealing at 66 C for 45 s, extension at
72 C for 45 s, extension at 72 C for 45 s and in the last cycle,
extension was prolonged to 7 min [4]. The ampliﬁed products
were then visualized by 4%agarose gel electrophoresis and visu-
alized on an ultraviolet transilluminator to detect the genotype
distribution and allelic frequencies of the polymorphisms, as
represented in Fig. 1.
Statistics. The results were analyzed using SPSS computer
software package, version 10.0 (Chicago, IL, USA). All data
were expressed as frequencies or mean and SD. Comparison
of quantitative data was done using student’s t-test. The differ-
ences in genotype and allele frequencies & their associations
with SLE clinical and immunological features were compared
by Chi-square (v2) and Fisher’s exact tests. Odd’s ratio (OR)
and 95% conﬁdence interval (CI) values were calculated. P
value of <0.05 was taken as signiﬁcant.
3. Results
Clinical data and SLE patients’ characteristics are summarized
in Table 1.
3.1. IL-6 promoter polymorphism (174 G/C) in SLE patients
compared to controls
As represented in Table 2, evaluation of genotypic and allelic
distributions showed no signiﬁcant difference between SLE pa-
tients and controls. Of the patients, 71.4% had the GG geno-
type (70% in the control group), 23.8% had the GC genotype
(30% in the control group) and 4.8% had the CC genotype
(0% in the control group). The frequency of G allele was high-
er than C allele in both patients (83.3% vs. 16.7%) and con-
trols (85% vs. 15%).
Table 1 Demographic and medical features of SLE patients.
SLE patients (n= 42)
Demographic data
Age
Range 25–43 yrs
Mean ± SD 32.4 ± 5.5 yrs
Disease duration
Range 4–9 yrs
Mean ± SD 5.7 ± 1.5 yrs
Clinical features
Constitutional manifestations
at disease onset
19/42 (45%)
Oral ulcers 15/42 (36%)
Malar rash 16/42 (38%)
Photosensitivity 25/42 (60%)
Serositis 14/42 (31%)
Arthritis 15/42 (36%)
Lupus nephritis 25/42 (60%)
CNS disease 6/42 (14%)
Hematological disorders 26/42 (62%)
Auto-antibodies
Seropositive ANAs 36/42 (86%)
Seropositive Anti-dsDNA 34/42 (81%)
Seropositive Anti Sm 10/42 (24%)
72 D. Abbas et al.3.2. IL-6 promoter polymorphism (174 G/C) and clinical and
laboratory manifestations of SLE
GG genotype and G allele were associated with signiﬁcantly
higher frequencies and increased risk of: constitutional mani-
festations at disease onset, photosensitivity, hematological dis-
orders and positivity of ANAs and Anti-dsDNA as shown in
details in Tables 3 and 4.
Furthermore, no signiﬁcant difference was found between
IL-6 genotypes concerning SLE laboratory features except
for WBCs counts as patients with GG genotype had signiﬁ-
cantly lower mean compared to SLE patients with (GC and
CC) genotypes (P= 0.002), as shown in Table 5.
3.3. IL-6 promoter polymorphism (-174 G/C) and Lupus
nephritis
Twenty-ﬁve patients had lupus nephritis (LN) proved by renal
biopsy but none of them had CC genotype. LN patients with
GG genotype had nearly similar mean 24-h proteinuria to
those with GC genotype (2.93 ± 1.07 vs. 2.68 ± 1.06 g/24 h
and P= 0.39).Table 2 Genotypic and allelic frequencies of the IL-6 promoter po
IL-6 promoter SLE patients (n= 42) Contro
Genotype
GG 30 (71.4%) 28 (70%
GC 10 (23.8%) 12 (30%
CC 2 (4.8%) 0 (0%)
Allele
G 70 (83.3%) 68 (85%
C 14 (16.7%) 12 (15%
a Fisher’s exact test was used.On assessment of the association between the IL-6 geno-
types and the histological WHO classes, no signiﬁcant differ-
ence was found in IL-6 genotype and allele distributions
when patients with diffuse proliferative glomerulonephritis
(class IV), which has the worst prognostic outcome, were com-
pared to patients with non-class IV glomerulonephritis (classes
II and III), as represented in Table 6. GG genotype’s and G
allele’s OR in patients with class IV LN was 0.23 (95% CI
0.04–1.51); 0.3 (95% CI 0.05–1.68), respectively.
4. Discussion
Recent immunogenetic studies demonstrated that polymor-
phisms at several loci, including the major histocompatibility
complex, complement proteins, immunoglobulin receptors,
cytokines and other as yet unmapped genes, are associated
with SLE, implying that the gene products of these loci are in-
volved in the pathogenesis of SLE [23].
In addition, clinical and experimental data suggest the IL-6
locus to be further candidate gene for SLE. Thus, IL-6 has
been shown to promote many immunopathological features
typical of SLE, such as polyclonal B-cell hyperactivity and
the production of autoantibodies. Moreover, IL-6 can be de-
tected in compartments involved in active disease [4].
GG homozygotes and G/C heterozygotes have been dem-
onstrated to have higher plasma IL-6 level, higher gene tran-
scriptional activity, and higher inducible IL-6 responses than
CC homozygous in systemic-onset juvenile chronic arthritis.
The reduced frequency of the potentially protective CC geno-
type in young patients may contribute to its pathogenesis [19].
In Primary Sjo¨gren syndrome, the G/C polymorphism of
IL-6 gene didn’t predispose patients to the disease. The G allele
seemed partly to determine the plasma level of IL-6, suggesting
that the presence of this allele may be a risk factor for some
extraglandular manifestations associated with high IL-6 con-
centration [24].
In the present work, genotypic and allelic distributions of
IL-6 promoter region (174 G/C) polymorphism showed no
signiﬁcant difference between SLE patients and controls. This
ﬁnding is explained either by that fact this polymorphism plays
no role in disease susceptibility or that SLE patients display
heterogeneity of their genetic background that masks its effect
[4,12].
Furthermore, it has been suggested that single nucleotide
polymorphisms at distinct polymorphic sites inﬂuence each
other and do not act independently of one another; thus, the
cooperative inﬂuence of genetic polymorphisms on develop-
ment of disease should also be considered [25].lymorphism in patients with SLE and controls.
ls (n= 40) X2 (P value) OR (95% CI)
) 0.2 (0.89) 1.1 (0.412.78)
) 0.4 (0.53) 0.74 (0.271.94)
(0.26)a
) 0.85 (0.77) 0.88 (0.382.04)
) 1.13 (0.492.63)
Table 3 Association of IL-6 genotypes and SLE clinical features and auto-antibody positivity proﬁles.
SLE patients with
GG genotype
SLE patients
with (GC and CC)
genotypes
P valuea OR (95% CI)
Clinical features
Constit. manifestations at disease onset (n= 19) 17 (89.5%) 12 (10.5%) 0.02 6.55 (1.22–35.12)
Oral ulcers (n= 15) 9 (60%) 6 (40%) 0.19 0.43 (0.11–1.7)
Malar rash (n= 16) 12 (75%) 4 (25%) 0.49 1.33 (0.33–5.43)
Photosensitivity (n= 25) 21 (84%) 4 (16%) 0.03 4.67 (1.11–19.54)
Serositis (n= 14) 9 (64.3%) 5 (35.7%) 0.3 0.6 (0.15–2.4)
Arthritis (n= 15) 9 (60%) 6 (40%) 0.19 0.43 (0.11–1.7)
Lupus nephritis (n= 25) 17 (68%) 8 (32%) 0.41 0.65 (0.16–2.65)
CNS disease (n= 6) 4 (66.7%) 2 (33.3%) 0.56 0.77 (0.12–4.88)
Hematological disorders (n= 26) 22 (84.6%) 4 (15.4%) 0.02 5.5 (1.29–23.39)
Auto-antibodies
ANAs (n= 36) 28 (77.7%) 8 (22.3%) 0.046 7 (1.1–45.44)
Anti-dsDNA (n= 34) 27 (79.4%) 7 (20.6%) 0.03 6.43 (1.23–33.65)
Anti Sm (n= 10) 8 (80%) 2 (20%) 0.4 1.82 (0.33- 10.16)
a Fisher’s exact test was used.
Table 4 Association of IL-6 gene allelic frequencies and some SLE clinical features and auto-antibody positivity proﬁles.
G allele C allele P valuea OR (95% CI)
Clinical features
Constit. manifestations at disease onset (n= 19) 36 (94.7%) 2 (5.3%) 0.01 6.35 (1.32–0.49)
Photosensitivity (n= 25) 46 (92%) 4 (8%) 0.01 4.79 (1.36–6.9)
Hematological disorders (n= 26) 47 (90.4%) 5(9.6%) 0.03 3.68 (1.12–2.23)
Auto-antibodies
ANAs (n= 36) 63 (87.5%) 9 (12.5%) 0.025 5 (1.3–9.16)
Anti-dsDNA (n= 34) 60 (88.2%) 8 (11.8%) 0.02 4.5 (1.29–5.75)
a Fisher’s exact test was used.
Table 5 Association of IL-6 genotypes and various laboratory ﬁndings.
SLE patients with GG
genotype (mean ± SD)
SLE patients with (GC and CC)
genotypes (mean ± SD)
P
value
ESR (mm/1st h) 55.62 ± 24.58 60.63 ± 14.14 0.51
Hb (gm/dl) 9.15 ± 2.03 9.59 ± 1.71 0.56
WBCs (dl) 4.54 ± 1.31 5.98 ± 1.04 0.002
PLT (dl) 190.45 ± 49.4 168.92 ± 62.21 0.24
Serum creatinine (mg/dl) 0.86 ± 0.75 0.91 ± 0.54 0.83
Serum C3 (g/l) 0.58 ± 0.53 0.46 ± 0.58 0.52
Serum C4 (g/l) 0.14 ± 0.14 0.07 ± 0.06 0.12
Normal values: serum creatinine 0.32–1.2 mg/dl, serum C3 0.9–1.8 g/l and serum C4 0.1–0.4 g/l.
Promoter region polymorphism (174 G/C) of interleukin-6 gene and SLE; are they associated? 73In literature, several studies revealed contradictory results
regarding the relationship between IL-6 promoter region
(174 G/C) polymorphism and SLE. The frequency of IL-6
(GG and GC) genotypes and G allele were demonstrated to
be signiﬁcantly higher in SLE patients than controls [26].
Moreover, homozygous G genotype patients were observed
to be predisposed to SLE development and those with hetero-
zygous G/C genotype could be protected from developing SLE
[27]. On the other hand, a number of studies reported lack ofassociation of the IL-6 gene polymorphism at position 174
with SLE [4,18,28].
The current study shows that GG genotype and G allele
were associated with signiﬁcantly higher frequencies and in-
creased risk of: constitutional manifestations at disease onset,
photosensitivity, hematological disorders and positivity of
ANAs and Anti-dsDNA compared to (GC and CC) genotypes
and C allele. This data suggest that the C allele has a masking
effect over the G allele in G/C heterozygous, which may be due
Table 6 Genotypic distribution of the IL-6 promoter polymorphism in LN patients with and without diffuse proliferative
glomerulonephritis.
GG genotype GC genotype P valuea G allele C allele P valuea
LN patients with WHO class IV (n= 13) 7 (53.8%) 6 (46.2%) 0.12 20 (76.9%) 6 (25.1%) 0.15
LN patients with WHO classes II and III (n= 12) 10 (83.3%)) 2 (16.7%) 22 (91.6%) 2 (8.3%)
a Fisher’s exact test was used.
74 D. Abbas et al.to a complex interaction of both alleles when present co-dom-
inantly as explained by Chau and coworkers [27].
The study was performed on Caucasian German patients
with SLE, IL-6 promoter polymorphisms at 174 G/C predis-
posed to distinct clinical and immunological features such as
discoid skin lesions and the production of anti-histone anti-
bodies in association with IL-6 high-responder allele (174
G) [4]. In the Iranian study, 174 G/C polymorphism was
associated with the presence of antinuclear antibodies (in all
patients) and rash and hematuria (in male patients) concluding
that IL-6 174 GG is important for the production of disease-
associated autoantibodies and some clinical manifestations
particularly in male patients [18].
In Chinese SLE patients, there were no signiﬁcant differ-
ences in IL-6 gene polymorphism between the SLE patients
concerning their clinical manifestations [28]. These controver-
sial results can be explained by the genetic heterogeneity of
SLE in different populations [29].
Although IL-6 has been found in cerebrospinal ﬂuid of SLE
patients with active CNS disease & in urine samples and kid-
ney biopsies of LN patients, in agreement with the ﬁndings
of Schott and associates [4], we did not ﬁnd an association
of IL-6 promoter region (174 G/C) polymorphism with neu-
ropsychiatric lupus, lupus nephritis or its severity. This may
has been due to the small number of patients with CNS lupus
included in our study. In addition, the existence of other po-
tent genetic regulatory elements or the non-speciﬁc IL-6 pro-
duction under inﬂammatory conditions or the modulated IL-
6 production by hormones, other cytokines and immuno-mod-
ulating therapy may be even more important reasons [4].
In conclusion, our data demonstrates that IL-6 promoter re-
gion (174 G/C) polymorphism does not confer susceptibility
to SLE but predisposes to constitutional manifestations at dis-
ease onset, photosensitivity, hematological disorders and the
production of ANAs and Anti-dsDNA. Furthermore, the in-
creased frequency of the high-response G allele suggests that
a genetically determined high IL-6 response may have a path-
ogenic role under these conditions.
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